Key facts
| Price (PPV) | 676 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | indacatérolglycopyrronium |
| Class | Drugs for obstructive airway diseases |
| ATC code | R03AL04 |
| Manufacturer | NOVARTIS PHARMA MAROC |
| Presentation | Boite de 30 |
| Nature | Médicament |
| Hospital price | 449 MAD |
| Data collected on | 9/8/2026 |
Indications
Ultibro Breezhaler est indiqué dans le traitement bronchodilatateur d'entretien chez les patients symptomatiques atteints de bronchopneumopathie chronique obstructive (BPCO) chez qui un traitement en monothérapie par LAMA ou LABA à faible dose n'est pas suffisant. Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Ultibro Breezhaler 110 mcg / 50 mcg
Ultibro Breezhaler 110 mcg / 50 mcg belongs to the drugs for obstructive airway diseases therapeutic class. In Morocco, this drug is marketed by NOVARTIS PHARMA MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Ultibro Breezhaler 110 mcg / 50 mcg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Ultibro Breezhaler 110 mcg / 50 mcg
Answers to common questions from Moroccan patients about this drug.